Nordicus Partners Corporation reported positive preclinical results for its subsidiaries' drugs targeting oral diseases: Orocidin's QR-01 showed efficacy in periodontitis animal models, Bio-Convert's QR-02 received a toxicity waiver and is on track for GMP manufacturing targeting oral leukoplakia, and NoviThera's QR-04 demonstrated biological proof of concept for psoriasis treatment. Phase IIa clinical trials for QR-01 and QR-02 are planned for the first half of 2027. The company is also pursuing a Nasdaq uplisting and exploring new acquisitions in the Nordic life sciences sector.
Ondo Finance has introduced the first tokenized stock representations backed by DTCC tokenized entitlements, joining major financial firms in a significant tokenization initiative. This move highlights Ondo's unique position in building infrastructur...
Leading Japanese companies, startups, and research institutions are developing specialized AI models using NVIDIA Nemotron open models to address Japan's unique language, industrial, and workforce challenges. These AI applications range from enterpri...
ERock, Inc. received a buy rating due to its innovative modular natural-gas power systems that help data centers avoid long waits for permanent grid power. The company has a strong $1.3 billion backlog supported by customer deposits, providing clear ...
IBM's business model remains strong despite a 7% decline in mainframe infrastructure revenue, supported by loyal legacy customers and solid free cash flow. Software growth, especially an 11% increase in Red Hat revenue, helps offset mainframe challen...
BMW is recalling 29,119 plug-in hybrid sedans due to a potential fire risk caused by corrosion in the engine starter's electrical relay. This defect can lead to a short circuit and overheating even when the vehicle is parked with the ignition off. Th...
